Products for Research Use Only

FR900359

CAT: 0804-HY-117037-01Size: 250 µgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-117037-01Size:250 µg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
FR900359 is a depsipeptide selective inhibitor of Gαq/11/14 in mammalia, can inhibits ERK pathway. FR900359 suppresses the proliferation of melanoma cells and decreases of blood pressure. FR900359 also protected against airway hyperreactivity in murine models of allergen sensitization in Ovalbumins –induced sensitization model of asthma. FR900359 can be used for cancer and cardiovascular disease research[1][2][3][4].
CAS Number
107530-18-7
UNSPSC
12352005
Hazard Statement
H225, H302+H312+H332, H319
Target
Apoptosis; ERK
Type
Natural Products
Related Pathways
Apoptosis; MAPK/ERK Pathway; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/fr900359.html
Purity
99.90
Solubility
10 mM in DMSO
Smiles
CC(C)[C@@H](O)[C@H](NC(CC)=O)C(O[C@@H]([C@H](NC([C@H](C)N(C)C([C@H](C)NC(C(N(C)C([C@@H](CC1=CC=CC=C1)O2)=O)=C)=O)=O)=O)C(N(C)[C@@H]([C@H](OC)C)C(O[C@H](C(C)C)[C@H](NC(C)=O)C2=O)=O)=O)C(C)C)=O
Molecular Formula
C49H75N7O15
Molecular Weight
1002.16
Precautions
H225, H302+H312+H332, H319
References & Citations
[1]Schrage R, et.al. The experimental power of FR900359 to study Gq-regulated biological processes. Nat Commun. 2015 Dec 14;6:10156. |[2]Fujioka, M, et.al. Structure of FR900359, a cyclic depsipeptide from Ardisia crenata sims J. Org. Chem. 1988, 53 (12), 2820−2825. |[3]Lapadula D, et.al. Effects of Oncogenic Gαq and Gα11 Inhibition by FR900359 in Uveal Melanoma. Mol Cancer Res. 2019 Apr;17 (4) :963-973. |[4]Matthey M, et.al. Targeted inhibition of Gq signaling induces airway relaxation in mouse models of asthma. Sci Transl Med. 2017 Sep 13;9 (407) :eaag2288.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Natural Products
Clinical Information
No Development Reported